Literature DB >> 17997282

Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994-2005.

F M E Wagenlehner1, A H Niemetz, W Weidner, K G Naber.   

Abstract

From 1994-2005, all uropathogens cultured from the urine of hospitalised urological patients were identified and their sensitivity was tested against the most important antibiotics for the treatment of urinary tract infection (UTI). Duplicate isolates were eliminated. The following results were obtained: (i) there was no general trend of increase in resistance; (ii) certain uropathogens developed resistance to some antibiotics; (iii) vancomycin- or linezolid-resistant staphylococci or enterococci did not play a role; (iv) the lowest overall rates of resistance were found with piperacillin/tazobactam; and (v) ciprofloxacin and trimethoprim/sulfamethoxazole showed the next favourable overall activity. Adequate initial antibiotic therapy is critical in the treatment of severe UTI. Therefore, ongoing surveillance of antibiotic resistance must be performed in every institution. Additionally, it reflects antibiotic and hospital infection policies in a defined department or institution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997282     DOI: 10.1016/j.ijantimicag.2007.07.029

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  Comparison of asymptomatic bacteriuria Escherichia coli isolates from healthy individuals versus those from hospital patients shows that long-term bladder colonization selects for attenuated virulence phenotypes.

Authors:  Ellaine Salvador; Florian Wagenlehner; Christian-Daniel Köhler; Alexander Mellmann; Jörg Hacker; Catharina Svanborg; Ulrich Dobrindt
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

2.  [Antimicrobial and clinical efficacy of nitrofurantoin in the treatment of acute lower urinary tract infections in adults].

Authors:  Arturo Mendoza-Valdes; Alejandra Rosete; Esteban Rios Bueno; Adrian Frentzel; Sonja Trapp; Wilhelm Kirch; Edgar A Mueller
Journal:  Med Klin (Munich)       Date:  2010-10

3.  Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.

Authors:  Tommaso Cai; Sandra Mazzoli; Francesca Meacci; Vieri Boddi; Nicola Mondaini; Gianni Malossini; Riccardo Bartoletti
Journal:  J Microbiol       Date:  2011-06-30       Impact factor: 3.422

4.  Transformation of Brevibacillus, a soil microbe to an uropathogen with hemagglutination trait.

Authors:  S C Suneeva; R Prasanth; N G Rajesh; P Viswanathan
Journal:  World J Microbiol Biotechnol       Date:  2014-01-24       Impact factor: 3.312

5.  Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis.

Authors:  Florian M E Wagenlehner; Christine Wagenlehner; Rebecca Redman; Wolfgang Weidner; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

6.  [Medical therapy of urinary tract infection].

Authors:  G Stein; R Fünfstück
Journal:  Internist (Berl)       Date:  2008-06       Impact factor: 0.743

7.  Urinary tract infections in women: etiology and treatment options.

Authors:  Daniele Minardi; Gianluca d'Anzeo; Daniele Cantoro; Alessandro Conti; Giovanni Muzzonigro
Journal:  Int J Gen Med       Date:  2011-04-19

Review 8.  Pharmacological Interventions for Bacterial Prostatitis.

Authors:  Situ Xiong; Xiaoqiang Liu; Wen Deng; Zhengtao Zhou; Yulei Li; Yechao Tu; Luyao Chen; Gongxian Wang; Bin Fu
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

9.  Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine.

Authors:  Christina F M van der Donk; Jeroen H B van de Bovenkamp; Els I G B De Brauwer; Patrick De Mol; Karl-Heinz Feldhoff; Wiltrud M Kalka-Moll; Sita Nys; Inge Thoelen; Thera A M Trienekens; Ellen E Stobberingh
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.